FDA Grants Accelerated Approval to Nuvalent’s Zidesamtinib (Jideytro) for ROS1-Positive NSCLC, Two Months Ahead of PDUFA Date

August 2, 2026

FDA USA

Overview

On July 22, 2026, the FDA approved Nuvalent, Inc.’s zidesamtinib (Jideytro) for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) previously treated with at least one ROS1 tyrosine kinase inhibitor (TKI). This accelerated approval, granted two months ahead of the target date, was based on results from the multi-center, single-arm, open-label ARROS-1 trial and utilized Orphan Drug Designation and the Real-Time Oncology Review (RTOR) pilot program.

In Depth

Key Findings

On July 22, 2026, the U.S. Food and Drug Administration (FDA) granted accelerated approval to zidesamtinib (Jideytro), a novel therapeutic developed by Nuvalent, Inc., for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have been previously treated with at least one ROS1 tyrosine kinase inhibitor (TKI). This swift approval provides a critical new treatment option for a serious disease, significantly accelerating patient access to this therapy.

Technical/Clinical Details

The approval of zidesamtinib was primarily based on the compelling results from the ARROS-1 clinical trial. This study, a multi-center, single-arm, open-label, multi-cohort trial, evaluated the safety and efficacy of zidesamtinib. The findings demonstrated clear clinical significance and benefit in pre-treated ROS1-positive NSCLC patients.

Trial Design: The ARROS-1 trial enrolled patients with previously treated ROS1-positive NSCLC to assess the efficacy and safety of zidesamtinib as a monotherapy.
Key Endpoints: Objective Response Rate (ORR) and Duration of Response (DoR) were critical efficacy endpoints. While specific numerical data for ORR and DoR were not detailed in the summary, the observed clinical benefits were sufficient for the FDA to grant accelerated approval.
Safety Profile: The reported safety data indicated an acceptable tolerability profile, with manageable rates of serious adverse events.

Furthermore, zidesamtinib received Orphan Drug Designation, which provides incentives for the development of drugs for rare diseases. The FDA actively leveraged its Real-Time Oncology Review (RTOR) pilot program and Assessment Aid tools to achieve this accelerated approval, two months earlier than the original Prescription Drug User Fee Act (PDUFA) target date. This highlights the FDA’s commitment to expediting innovative cancer treatments to patients with urgent needs.

Background & Context

ROS1-positive NSCLC is a distinct subtype of non-small cell lung cancer caused by specific genetic alterations, accounting for approximately 1-2% of all NSCLC cases. Patients with this subtype often have limited responses to conventional chemotherapy, and targeted therapies with ROS1 TKIs have become the standard of care. However, a significant unmet need exists for patients who develop resistance to existing ROS1 TKIs. The approval of zidesamtinib offers a crucial therapeutic option for these previously treated patients, with the potential to improve their prognosis.Strategic Significance & Outlook

The approval of zidesamtinib marks a significant milestone for ROS1-positive NSCLC patients, especially those whose disease has progressed after prior TKI treatment. Given its potent mechanism of action and favorable clinical data, the drug is expected to address critical unmet medical needs in this challenging disease area. Future accumulation of clinical data and evaluation of its efficacy in combination with other therapies will further enhance zidesamtinib’s clinical value. Nuvalent, Inc. aims to establish leadership in the ROS1-positive NSCLC treatment landscape with this foundational approval, impacting global patient care by providing advanced, targeted treatment options.

Source: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zidesamtinib-ros1-positive-non-small-cell-lung-cancer

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.